Overview
TB-500 is a synthetic peptide derived from thymosin beta-4 (TB4), a 43-amino acid protein naturally present in nearly all nucleated cells of the body. Thymosin beta-4 was initially isolated from the thymus in the 1960s, but subsequent research revealed its ubiquitous expression in human tissues, with particularly high concentrations in blood platelets, leukocytes, and migrating cells.
TB-500 contains the active sequence of thymosin beta-4, notably the central LKKTETQ domain, identified as the primary motif responsible for the protein's biological activity on cell migration and tissue repair. This fragment retains the key properties of the parent molecule while offering better experimental manageability and a reduced molecular mass.
Thymosin beta-4 is the main sequestering peptide of G-actin (monomeric actin) in eukaryotic cells. This fundamental function in actin cytoskeleton regulation gives it a central role in cell motility, morphogenesis, and tissue repair processes. Research on TB-500 falls within the broader field of regenerative medicine and wound healing biology. TB-500 is a key component of blends such as Klow Peptide and Glow Peptide.
In Europe, TB-500 is also available as a pre-filled pen. Our guide to pre-filled peptide pens explains how this format differs from a vial (price per mg, stability).
Mechanism of Action
The primary mechanism of action of TB-500 is based on actin cytoskeleton regulation. Thymosin beta-4 binds to monomeric G-actin with a 1:1 stoichiometry, forming a complex that prevents spontaneous polymerization of actin into filaments (F-actin). By regulating the available G-actin pool, TB-500 controls cytoskeletal dynamics, a process essential for cell migration, lamellipodia formation, and cytokinesis.
Beyond actin sequestration, TB-500 activates several signaling pathways involved in tissue repair. It stimulates the Akt/mTOR pathway, promoting cell survival and apoptosis inhibition. The peptide also induces the expression of vascular endothelial growth factor (VEGF) and angiopoietin-1, promoting angiogenesis in injured tissues. Studies have shown that TB-500 upregulates laminin-5 and beta-3 integrin, proteins involved in cell adhesion and migration.
TB-500 also exerts significant anti-inflammatory effects. It modulates the NF-kB pathway, reducing the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and attenuating inflammatory cell recruitment to the injury site. This dual action, pro-regenerative and anti-inflammatory, creates a microenvironment favorable to wound healing, limiting fibrotic scar tissue formation in favor of more complete tissue regeneration.
Studied Benefits
Post-infarction cardiac repair
Preclinical studies in murine models of myocardial infarction have shown that thymosin beta-4 reduces the size of the infarcted area, improves left ventricular contractile function, and stimulates neovascularization of injured cardiac tissue. These effects are attributed to the activation of cardiac progenitor cells and the anti-apoptotic effect of the peptide.
Accelerated skin wound healing
Thymosin beta-4 accelerates skin wound healing in animal models by stimulating keratinocyte and endothelial cell migration, increasing angiogenesis, and promoting organized collagen deposition. Studies on chronic wound models (diabetic) show a significant improvement in closure time.
Neuroprotection and neuronal regeneration
Research on models of traumatic brain injury and stroke has shown that thymosin beta-4 reduces neuronal inflammation, promotes oligodendrocyte survival, and stimulates remyelination. The peptide improves functional neurological scores in animal models of central nervous system injuries.
Corneal injury repair
One of the most clinically advanced applications of thymosin beta-4 concerns corneal wound healing. Phase II clinical trials (RGN-259) have evaluated the efficacy of topical ophthalmic thymosin beta-4 in the treatment of dry eye disease and neurotrophic corneal lesions, with encouraging results.
Research Status
Research on thymosin beta-4 and TB-500 covers a broad disciplinary spectrum, from fundamental cell biology to clinical trials. The scientific literature comprises over 300 peer-reviewed publications, with a notable acceleration of research since the pioneering work of Sosne and Kleinman on regenerative effects in the 2000s.
The most robust preclinical studies concern regenerative cardiology and skin wound healing. The work of Bock-Marquette and collaborators (2004) demonstrated the cardioprotective effect of thymosin beta-4 in a murine model of myocardial ischemia, a finding confirmed by several independent teams. In ophthalmology, the clinical development of RGN-259 (topical thymosin beta-4 formulation) represents the most advanced therapeutic application, with Phase II/III trials for dry eye disease.
Current limitations include the complexity of the mechanisms of action, which makes it difficult to identify predictive biomarkers of response, the lack of detailed pharmacokinetic data for synthetic TB-500, and the difficulty of translating effective doses from animal models to humans. TB-500 is also listed on the World Anti-Doping Agency (WADA) prohibited substances list, due to its potential for enhancing tissue recovery.
Safety and Side Effects
The safety profile of thymosin beta-4 is generally favorable in published preclinical studies. Acute and chronic toxicity studies in rodents and dogs have not revealed significant toxicity at therapeutic doses. In ophthalmic clinical trials (RGN-259), the topical thymosin beta-4 formulation was well tolerated, with no serious adverse effects attributable to the treatment.
A theoretical concern involves the potential role of thymosin beta-4 in tumor progression. Indeed, elevated levels of thymosin beta-4 have been observed in certain types of tumors, and the peptide could theoretically promote tumor angiogenesis and metastasis by increasing cell motility. However, available studies do not demonstrate that exogenous administration of thymosin beta-4 induces or accelerates carcinogenesis, and the peptide has even shown anti-tumor effects in certain models.
For TB-500 specifically, human safety data are limited, as the majority of clinical trials use complete thymosin beta-4 rather than the synthetic fragment. Anecdotally reported side effects include transient headaches, mild lethargy, and injection site discomfort. The use of TB-500 remains within the scope of experimental research, and its status as a WADA-prohibited substance underscores the need for strict oversight.
Legal and regulatory status by region
United States. No medicine containing TB-500 is approved by the FDA. In its briefing document for the Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026, FDA described TB-500 as the seven-amino-acid fragment Ac-LKKTETQ (thymosin beta-4 residues 17-23) and recommended against adding TB-500 (free base) or TB-500 acetate to the 503A bulks list. On 28 October 2026, HHS issued an enforcement-discretion policy (Federal Register notice 2026-22192, published 30 October 2026). HHS does not intend to take enforcement action against State-licensed 503A pharmacies, Federal facilities or licensed physicians that compound TB-500 acetate in subcutaneous or intramuscular injectable forms, under conditions: a patient-specific prescription, an active ingredient from an FDA-registered manufacturer with a certificate of analysis, a single active ingredient (no blends) and a 510(k)-cleared syringe.
The substance named in the HHS appendix is the acetate salt of the fragment (C38H68N10O14·CH3COOH, 949.1 g/mol). The policy does not cover full-length thymosin beta-4. It is temporary while FDA rulemaking on the 503A bulks list continues, it is not an approval and not a listing on that list, and it excludes 503B outsourcing facilities and products sold for research use only.
Sport. The WADA 2026 Prohibited List names "thymosin-β4 and its derivatives e.g. TB-500" among the growth factors of class S2 (peptide hormones, growth factors, related substances and mimetics). Class S2 is prohibited at all times, in and out of competition.
Australia. The Poisons Standard (October 2026 instrument) lists both TB-500 and thymosin beta 4 in Schedule 4 (prescription-only medicines) and in Appendix D, clause 5: poisons that must not be possessed without authority, for example without a legal prescription.
European Union and United Kingdom. No medicine containing TB-500 or thymosin beta-4 holds a marketing authorisation from the EMA or the MHRA. A product presented with medicinal claims is regulated as a medicine in both regions, whatever its "research use only" label, and national rules on import and possession vary.
What the evidence does not show
- No controlled human trial of the fragment for injuries. FDA's 2026 review did not identify any clinical study of TB-500 in humans, and none of the 43 references submitted with the nomination studied TB-500 in people. FDA also found no in vivo study of TB-500 for wound healing; in the one cell study it identified, TB-500 did not induce closure of scratch wounds in fibroblast cultures. A 2026 orthopaedic review found that direct musculoskeletal evidence for thymosin beta-4 is limited to cell and rodent studies (Tham et al., 2026).
- The human trials concern full-length thymosin beta-4. RegeneRx and ReGenTree tested thymosin beta-4 eye drops (RGN-259) in dry eye and neurotrophic keratopathy, and earlier in skin ulcers. Beijing Northland Biotech is testing recombinant thymosin beta-4 (NL005) given intravenously after myocardial infarction. These results cannot be transferred to a 7-amino-acid fragment, because the two have not been shown to be biologically equivalent.
- Long-term safety is unknown. FDA found no genotoxicity, reproductive toxicity or carcinogenicity studies of TB-500. Animal data show that the fragment is broken down into smaller peptides, and the HHS appendix notes that it is rapidly truncated in human serum. The safety record of full-length thymosin beta-4 does not settle the safety of the fragment.
- The content of a vial is uncertain. FDA reports that several salts and derivatives, including different active moieties, are sold under the name TB-500; in the nomination it reviewed, the molecular formula matched neither the free base nor the acetate. A French horse-racing laboratory found that TB500 and TB1000 products bought online did not consistently match their description (Delcourt et al., 2023).
Human research in 2025-2026
As of November 2026, no peer-reviewed study of TB-500 (Ac-LKKTETQ) in humans has been published, and FDA's July 2026 review did not identify one. Human research continues on full-length thymosin beta-4:
- Myocardial infarction (recombinant thymosin beta-4, NL005). A phase 1 study in 84 healthy volunteers reported only mild to moderate adverse events and no serious adverse events (Wang et al., 2021). Beijing Northland Biotech then completed a phase 2b trial in 90 patients treated by PCI (NCT05984134, completed May 2023, no results posted). A phase 2c trial in 189 patients with STEMI (NCT07586865) is registered with infarct size on cardiac MRI at 90 days as its main endpoint; it was listed as not yet recruiting.
- Eye (RGN-259 eye drops). ReGenTree's phase 3 SEER-2 trial in neurotrophic keratopathy (NCT05555589, 70 participants) was completed in July 2026. No results had been posted on ClinicalTrials.gov at the time of writing.
- Reviews. Narrative reviews published in 2026 in Sports Medicine and in the Journal of the American Academy of Orthopaedic Surgeons conclude that rigorous human safety data are scarce and that TB-500 is frequently conflated with full-length thymosin beta-4 without any proven equivalence (Mendias and Awan, 2026; Tham et al., 2026).
Recommended products
Research peptides selected for quality and purity:
BPC-157 + TB-500
Healing Blend
TB-500
Recovery Peptide
BPC-157
Healing Peptide
GHK-Cu
Anti-Aging Compound
GHK-Cu Pen
Pre-filled Pen GHK-Cu
GLOW-UP Ritual
3-pen pack: Glow, NAD+, GHK-Cu
Test your knowledge
Quick quiz · 6 questions
TB-500: all our articles
- TB-500 Before and After: What a Realistic Results Timeline Looks Like
- TB-500 Side Effects: What the Research Literature Actually Shows
- Oral TB-500 Capsules: What Bioavailability Really Means
- BPC-157 vs TB-500: A Complete Comparison of Two Repair Peptides
- Where to Buy TB-500 in 2026
- The BPC-157 + TB-500 Stack: What the Recovery Research Actually Says
- TB-500 Dosage: Loading, Maintenance, and Reconstitution Protocols
- TB-500 pen: what it is, what it costs and where to buy it
- TB-500 for Horses and Dogs: What the Evidence and the Rulebooks Actually Say
- Where to Buy a BPC-157 + TB-500 Blend: A Research Buyer's Guide
- TB-500 and the Prescription Route in the United States
Frequently Asked Questions
What is the difference between TB-500 and thymosin beta-4?
Is TB-500 banned in sports?
What are the most advanced research areas for TB-500?
Can TB-500 promote cancer?
What is the exact chemical identity of TB-500?
What does the HHS policy of October 2026 change for TB-500?
Has TB-500 been tested in human clinical trials?
Scientific Sources
- Goldstein AL, Hannappel E, Sosne G, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51. (PubMed · DOI)
- Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466-472. (PubMed · DOI)
- Sosne G, Qiu P, Goldstein AL, et al. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal, 24(7), 2144-2151. (PubMed · DOI)
- Philp D, Badamchian M, Scheremeta B, et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19-24. (PubMed · DOI)
- Crockford D, Turjman N, Allan C, et al. (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 1194(1), 179-189. (PubMed)
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis, 4(9), 733-738. (PubMed · DOI)
- Delcourt V, Garcia P, Chabot B, et al. (2023). TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis, 15(4), 458-464. (PubMed · DOI)
- Wang X, Liu L, Qi L, et al. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine, 25(17), 8222-8228. (PubMed · DOI)
- Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 56(8), 1921-1935. (PubMed · DOI)
- Tham A, Hodgkins CW, Kennedy JG (2026). Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Journal of the American Academy of Orthopaedic Surgeons (online ahead of print). (PubMed · DOI)
- National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 62707662, TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH). PubChem. (pubchem.ncbi.nlm.nih.gov)
- U.S. Food and Drug Administration (2026). FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026: TB-500-related bulk drug substances (TB-500 free base and TB-500 acetate). FDA. (fda.gov)
- U.S. Department of Health and Human Services (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice 2026-22192, docket HHS-OASH-2026-0496). Federal Register, 30 October 2026. (federalregister.gov)
- World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2026 (S2, growth factors: thymosin-β4 and its derivatives e.g. TB-500). WADA. (wada-ama.org)
- Australian Government, Federal Register of Legislation (2026). Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (F2026L01327): TB-500 and thymosin beta 4, Schedule 4 and Appendix D clause 5. legislation.gov.au. (legislation.gov.au)
- Beijing Northland Biotech. Co., Ltd. (2026). Phase IIc study of recombinant human thymosin beta 4 injection (NL005) in patients with acute myocardial infarction (NCT07586865). ClinicalTrials.gov. (clinicaltrials.gov)
- Beijing Northland Biotech. Co., Ltd. (2023). Efficacy and safety of recombinant human thymosin β4 (NL005) for injection in patients with acute myocardial infarction: a phase IIb clinical study (NCT05984134). ClinicalTrials.gov. (clinicaltrials.gov)
- ReGenTree, LLC (2026). SEER-2: phase 3 study of 0.1% RGN-259 ophthalmic solution for neurotrophic keratopathy (NCT05555589). ClinicalTrials.gov. (clinicaltrials.gov)